ORGANOVO HOLDINGS INC (ONVO)

Company Profile

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2013-08-02. The firm uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. The company is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The firm uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.

Company Info

ORGANOVO HOLDINGS INC

Suite 110, 6275 Nancy Ridge Drive

San Diego CALIFORNIA 92075

P: 18585509994

CEO: Keith Murphy

Employees: 15

Website: https://organovo.com/